Mark Meininghaus is a Senior Research Scientist at Bayer Pharmaceuticals, specializing in cell-based assay development with a particular focus on miniaturized iPSC-derived cardiomyocyte setups. With over 20 years of experience in ultra-high throughput screening on cutting-edge robotic platforms, they have contributed to various roles within Bayer since 2007. Mark also held a position as a Senior Research Associate at the Broad Institute of MIT and Harvard in 2016.
This person is not in the org chart
This person is not in any teams
This person is not in any offices